PAREXEL Expands Market Access and Clinical Evidence Services
November 09 2015 - 7:00AM
Business Wire
Greater emphasis on medical affairs,
commercialization and lifecycle management for biopharmaceutical
products
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced
expanded evidence-based services for biopharmaceutical products.
PAREXEL® Access focuses on clinical research and operations, market
access consulting, medical communications, and pharmacovigilance to
help companies identify, evaluate, generate and communicate the
evidence of product value needed to successfully position a drug
for market access and to support the product throughout its
lifecycle.
It is estimated that the average cost to develop and gain
marketing approval for a new prescription medicine, a process often
lasting longer than a decade, is now $2.56 billion.1 To ensure a
return on investment, the transition from clinical research and
development to regulatory approval and commercial growth requires
thorough data and specialized strategic expertise that integrates
scientific and commercial insights.
“No longer is demonstrating safety and efficacy enough to launch
a product successfully. The pressures to control the cost of
healthcare coupled with the development of payer oversight
organizations mean drug developers must demonstrate clear value to
add a product to the treatment landscape,” said Joshua Schultz,
Corporate Vice President and Worldwide Head of PAREXEL Access,
PAREXEL.
PAREXEL Access combines the expertise of HERON™
Commercialization, QSI’s pharmacovigilance, PAREXEL Medical
Communications, and PAREXEL Peri-/Post-approval services to offer a
complete range of fully-integrated services to help clients
position their products for market access and ongoing commercial
success, including:
- Evidence Identification and
Evaluation: Aligning evidence generation and economic
evaluation with pricing, reimbursement and market access strategy
to enable our clients to make data-driven decisions to support
reimbursement.
- Evidence Generation: Providing
services to clients to generate evidence of a product’s value
through a range of global study types, including interventional
trials, observational research, managed access programs, real-world
evidence studies and drug safety programs.
- Communication: Developing the
best way to integrate complex scientific and economic data into
insightful communications for key audiences, including payers,
providers, patients, and policy makers.
Schultz added, “By combining our deep experience, innovative
strategies, and the industry’s best minds, PAREXEL Access offers an
unrivaled team of experts located throughout the world to support
our clients.”
For more information about PAREXEL Access, visit
www.PAREXEL.com/solutions/access.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 80
locations in 51 countries around the world, and had approximately
18,620 employees in the first quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL is a registered trademark of PAREXEL International
Corporation or its affiliates.
This release contains “forward-looking” statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the
words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. The
Company’s actual future results may differ materially from the
results discussed in the forward-looking statements contained in
this release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from restructurings, including expense
savings from the $30 – $45 million restructuring charge disclosed
in the press release dated June 23, 2015; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company’s recognition of revenue included in backlog;
the Company’s dependence on certain industries and clients; the
Company’s ability to win new business, manage growth and costs, and
attract and retain employees; the Company’s ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition of Quantum Solutions India, or enter into
new lines of business; the impact on the Company’s business of
government regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties;
the potential adverse impact of health care reform; and the effects
of foreign currency exchange rate fluctuations and other
international economic, political, and other risks. Such factors
and others are discussed more fully in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
1 Tufts CSDD Outlook 2015
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151109005094/en/
PAREXEL InternationalCristi Barnett,
+1-781-434-4019Cristi.Barnett@PAREXEL.comorPAN
CommunicationsMatthew Briggs,
+1-617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024